RxDoctor Payments Data

Clayton Flanary, DO

Internal Medicine · Tulsa, OKNPI 1740215680

Payments from drug & device makers

$885in general payments, 2019–2025

Across 63 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$265
  • Novo Nordisk$183
  • Pfizer$125
  • AstraZeneca$65
  • GSK$60
  • Exact Sciences$48
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC18$265
Novo Nordisk16$183
Pfizer9$125
AstraZeneca4$65
GSK4$60
Exact Sciences3$48
Sanofi-aventis U.S. LLC3$38
Dexcom, Inc.2$36
Kadmon Pharmaceuticals LLC1$18
AbbVie1$18
Amgen1$17
Beckman Coulter, Inc.1$13

How this compares

$885 in reported general payments places this provider in the 65th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,114
Medicare patients
230
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide238$232,343
MounjaroTirzepatide149$179,098
EliquisApixaban142$122,863
JardianceEmpagliflozin48$52,970
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$44,261
FarxigaDapagliflozin Propanediol36$35,847
XifaxanRifaximin11$34,716
JanuviaSitagliptin Phosphate44$30,307
EntrestoSacubitril/Valsartan22$28,978
XareltoRivaroxaban19$20,253
Breo ElliptaFluticasone/Vilanterol40$16,659
BrilintaTicagrelor16$11,261
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$11,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$9,774
JanumetSitagliptin Phos/Metformin Hcl14$8,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$183$232,343238 claims
Lilly USA, LLCMounjaro$265$179,098149 claims
PfizerEliquis$125$122,863142 claims
GSKTrelegy Ellipta, Breo Ellipta$60$60,921102 claims
AstraZenecaFarxiga, Brilinta, Symbicort$65$50,34665 claims
Sanofi-aventis U.S. LLCLantus$38$5,75833 claims
AbbVieSynthroid$18$3,91553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →